Nurse Practitioner, Adult Health · Asheboro, NC
NPI
1003949843
Since 2007
Specialty
Nurse Practitioner, Adult Health
Code 363LA2200X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
500 Albemarle Rd
Asheboro, NC, 27203
Phone (336) 625-1172
Groups this clinician bills Medicare through
Medicare paid, 2024
$60K
1,549 services
Medicare patients, 2024
354
Average age 75
Drug cost, 2024
$807K
961 prescriptions
Company payments, 2025
$1,901
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Deanna G Markham was code 17003 (destruction skin lesion), 302 times for 56 patients. In total Deanna G Markham billed 1,549 services in 33 codes, and Medicare paid $60K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-03-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 302 | 56 | $3.91 | $1,181 |
| 88305 Surgical Pathology Examination | Office | 287 | 163 | $41.30 | $12K |
| 11102 Skin Biopsy | Office | 188 | 158 | $45.05 | $8,469 |
| 99214 Office E&M - Established | Office | 141 | 128 | $63.88 | $9,008 |
| 99213 Office E&M - Established | Office | 139 | 120 | $49.09 | $6,824 |
| 17110 Destruction Skin Lesion | Office | 108 | 97 | $61.85 | $6,679 |
| 17000 Destruction Skin Lesion | Office | 95 | 80 | $26.42 | $2,510 |
| 11103 Skin Biopsy | Office | 79 | 53 | $27.11 | $2,142 |
| 99212 Office E&M - Established | Office | 33 | 33 | $28.17 | $930 |
| 99203 Office E&M - New | Office | 31 | 31 | $45.61 | $1,414 |
| 99204 Office E&M - New | Office | 11 | 11 | $69.49 | $764 |
By year: 2023 $45K for 1,076 services; 2024 $60K for 1,549 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 287 | 163 | $41.30 | $12K |
Medicare prescription drug claims, 2024
In 2024, the drug Deanna G Markham prescribed most often to Medicare patients was Triamcinolone Acetonide, with 179 prescriptions and refills. In total Deanna G Markham wrote 961 Medicare prescriptions that cost $807K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 179 | 194 | 129 | $1,695 |
| Finasteride Generic | 134 | 313 | 43 | $1,321 |
| Ketoconazole Generic | 87 | 91 | 48 | $1,314 |
| Doxycycline Hyclate Generic | 85 | 95 | 37 | $1,245 |
| Metronidazole Generic | 63 | 66 | 40 | $3,410 |
| Nystatin Generic | 40 | 43 | 26 | $417 |
| Mupirocin Generic | 39 | 40 | 32 | $274 |
| Fluconazole Generic | 30 | 47 | 19 | $441 |
| Otezla Apremilast | 25 | 25 | Under 11 | $122K |
| Dupixent Syringe Dupilumab | 25 | 25 | Under 11 | $95K |
| Taltz Syringe Ixekizumab | 23 | 23 | Under 11 | $157K |
| Hydroxychloroquine Sulfate Generic | 22 | 31 | Under 11 | $895 |
| Ammonium Lactate Generic | 20 | 20 | 15 | $567 |
| Clobetasol Propionate Generic | 20 | 20 | 14 | $674 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 18 | 18 | 17 | $50.32 |
Brand drugs: 134 claims; generic drugs: 827 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Deanna G Markham $1,901 ($1,901 in general payments such as food, travel and fees) from 18 companies. The largest payer was Abbvie Inc. with $385.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 20 | $385 |
| Genzyme Corporation SNY | 10 | $258 |
| UCB, Inc. UCB.BR | 8 | $186 |
| Arcutis Biotherapeutics, Inc. ARQT | 11 | $179 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $171 |
| Janssen Biotech, Inc. JNJ | 10 | $148 |
| Organon LLC OGN | 7 | $114 |
| Pfizer Inc. PFE | 5 | $94.81 |
| Galderma Laboratories, L.P. GALD.SW | 4 | $88.45 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $73.09 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.